Artículo
A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice
Coria, Mirta Lorena
; Saposnik, Lucas Martín
; Pueblas Castro, Celeste Victoria
; Castro, Eliana Florencia
; Bruno, Laura Alejandra; Stone, William B.; Pérez, Paula Soledad
; Darriba, Maria Laura
; Chemes, Lucia Beatriz
; Alcain, Julieta María
; Mazzitelli, Ignacio Gabriel
; Varese, Augusto
; Salvatori, Melina
; Auguste, Albert J.; Alvarez, Diego Ezequiel
; Pasquevich, Karina Alejandra
; Cassataro, Juliana
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
![Icon](/themes/CONICETDigital/images/conicet.png)
Fecha de publicación:
02/2022
Editorial:
Frontiers Media
Revista:
Frontiers in Immunology
ISSN:
1664-3224
Idioma:
Inglés
Tipo de recurso:
Artículo publicado
Clasificación temática:
Resumen
In this work, we evaluated recombinant receptor binding domain (RBD)-based vaccine formulation prototypes with potential for further clinical development. We assessed different formulations containing RBD plus alum, AddaS03, AddaVax, or the combination of alum and U-Omp19: a novel Brucella spp. protease inhibitor vaccine adjuvant. Results show that the vaccine formulation composed of U-Omp19 and alum as adjuvants has a better performance: it significantly increased mucosal and systemic neutralizing antibodies in comparison to antigen plus alum, AddaVax, or AddaS03. Antibodies induced with the formulation containing U-Omp19 and alum not only increased their neutralization capacity against the ancestral virus but also cross-neutralized alpha, lambda, and gamma variants with similar potency. Furthermore, the addition of U-Omp19 to alum vaccine formulation increased the frequency of RBD-specific geminal center B cells and plasmablasts. Additionally, U-Omp19+alum formulation induced RBD-specific Th1 and CD8+ T-cell responses in spleens and lungs. Finally, this vaccine formulation conferred protection against an intranasal severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) challenge of K18-hACE2 mice.
Palabras clave:
ADJUVANT
,
GERMINAL CENTER CELLS
,
PROTEASE INHIBITOR
,
SARS- COV-2
,
U-OMP19
,
COVID-19
Archivos asociados
Licencia
Identificadores
Colecciones
Articulos (IIBIO)
Articulos de INSTITUTO DE INVESTIGACIONES BIOTECNOLOGICAS
Articulos de INSTITUTO DE INVESTIGACIONES BIOTECNOLOGICAS
Articulos (IVIT)
Articulos de INSTITUTO DE VIROLOGIA E INNOVACIONES TECNOLOGICAS
Articulos de INSTITUTO DE VIROLOGIA E INNOVACIONES TECNOLOGICAS
Articulos(INBIRS)
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS EN RETROVIRUS Y SIDA
Articulos de INSTITUTO DE INVESTIGACIONES BIOMEDICAS EN RETROVIRUS Y SIDA
Citación
Coria, Mirta Lorena; Saposnik, Lucas Martín; Pueblas Castro, Celeste Victoria; Castro, Eliana Florencia; Bruno, Laura Alejandra; et al.; A Novel Bacterial Protease Inhibitor Adjuvant in RBD-Based COVID-19 Vaccine Formulations Containing Alum Increases Neutralizing Antibodies, Specific Germinal Center B Cells and Confers Protection Against SARS-CoV-2 Infection in Mice; Frontiers Media; Frontiers in Immunology; 13; 2-2022; 1-17
Compartir
Altmétricas